Comera Life Sciences Holdings, Inc. CMRA
At closeNov 2, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 3.07K
- Revenue (ttm)
- 1.00M
- EPS (ttm)
- -0.11
- Shares out
- 30.74M
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 730
- Avg volume
- 495
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0001
- Beta
- 0.45
15m 0.0000 (0.00%)
Key statistics
- Enterprise value
- 5.97M
- PEG ratio
- 0.00
- Price / sales
- 2.57
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -42.00%
- Free cash flow
- -2.99M
- Total cash
- 1.77M
- Total debt
- 561.47K
- Return on equity
- -1629.02%
- Short % of float
- 1.36%
- 50-day average
- 0.21206
- 200-day average
- 0.542355
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.10 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.08 | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | -0.13 | — | — |
| Mar 16, 2023 | Dec 1, 2022 | 0.00 | -0.18 | — | — |
| Nov 10, 2022 | Sep 1, 2022 | 0.00 | -0.20 | — | — |
About Comera Life Sciences Holdings, Inc.
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- comeralifesciences.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CMRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BANERJEE SIRSHENDU ROOPOM | Director | Stock Award(Grant) | Jan 3, 2023 | 28,956 |
| CAMPBELL MICHAEL GERARD | Chief Financial Officer | Purchase | Nov 26, 2023 | 35,000 |
| CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 10, 2023 | 7,368,390 |
| FINCK BARBARA K | Director | Stock Award(Grant) | Jan 3, 2023 | 23,033 |
| FLOWERS KIRSTEN | Director | Stock Award(Grant) | Jan 3, 2023 | 22,199 |
| MAHONEY ROBERT PATRICK | Officer | Purchase | Aug 13, 2023 | 124,576 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lake Street Advisors Group, LLC | 1.16% | 316,469 | 154.25K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.22% | 60,008 | 29.25K | Jun 29, 2023 |
| HighTower Advisors, LLC | 0.18% | 47,600 | 23.20K | Jun 29, 2023 |
| Vanguard Group Inc | 0.16% | 44,098 | 21.49K | Jun 29, 2023 |
| State Street Corporation | 0.11% | 29,600 | 14.43K | Jun 29, 2023 |
| Osaic Holdings Inc | 0.07% | 18,750 | 9.14K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.16% | 42,717 | 21.79K | May 30, 2023 |
| Vanguard Extended Market Index Fund | 0.16% | 44,098 | 21.49K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.04% | 10,925 | 5.57K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 4,547 | 2.32K | May 30, 2023 |